History of metastatic pancreatic neuroendocrine tumor. Surveillance study. ABDOMEN:LIVER, BILIARY TRACT: Multiple arterially peripherally enhancing metastatic liver lesions are again noted.The index segment 5 lesion measures approximately 2.1 cm x 1.8 cm (series 13/46), compared to 2.1 x 1.8 cm previously.The index segment 6 lesion measures approximately 2.2 x 1.9 cm (series 13/62), compared to 2.0 x 1.9 cm previously.The remaining lesions are not significantly changed in size or number.Susceptibility artifact from CBD stent. No significant intra or extrahepatic biliary ductal dilatation. The hepatic vasculature appears patent. Normally distended gallbladder.SPLEEN: No significant abnormality noted.PANCREAS: There is a poorly defined pancreatic head lesion measuring approximately 1.9 x 1.8 cm (series 13/70), compared to 2.1 x 1.4 cm previously. There is upstream pancreatic parenchymal atrophy without significant ductal dilatation.ADRENAL GLANDS: No significant abnormality noted.KIDNEYS, URETERS: No significant abnormality noted.RETROPERITONEUM, LYMPH NODES: No significant abnormality noted.BOWEL, MESENTERY: No significant abnormality noted.BONES, SOFT TISSUES: No significant abnormality noted.OTHER: No significant abnormality noted.
1.Stable examination with numerous arterial enhancing liver metastases.2.Relatively stable size of the pancreatic head lesion. 3.No new sites of disease.